10.10.2019 Biofrontera AG  DE0006046113

DGAP-Adhoc: Biofrontera AG: ​​​​​​​Biofrontera reports preliminary unaudited sales revenue for the first nine months of 2019


 

DGAP-Ad-hoc: Biofrontera AG / Key word(s): Quarter Results/9 Month figures
Biofrontera AG: ​​​​​​​Biofrontera reports preliminary unaudited sales revenue for the first nine months of 2019

10-Oct-2019 / 11:15 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Biofrontera reports preliminary unaudited sales revenue for the first nine months of 2019

Leverkusen, Germany, 10.10.2019 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company" or the "Biofrontera-group"), an international biopharmaceutical company, today reports preliminary unaudited revenue for the third quarter of fiscal year 2019.

The Biofrontera-Group generated sales of approximately EUR 18.9 to 19.2 million in the period from January 1st to September 30th, 2019. This corresponds to a sales growth of about 30% compared to the same period last year (EUR 14.6 million).
Preliminary unaudited nine-month sales of Ameluz(R) in the U.S. were between EUR 12.8 and 13.0 million, compared to EUR 10.2 million (approximately +25%) in the same period in 2018. Product sales of Xepi(TM) and AKTIPAK(R) contributed about EUR 0.7 million to sales since the acquisition of Cutanea Life Sciences, Inc. in late March 2019. Revenue in Germany increased by about 60% to EUR 3.1 to 3.3 million in the reporting period compared to EUR 2.1 million in the first nine months of 2018. In the remainder of Europe product sales were between 1.7 to 1.9 million, compared to 2.1 million (approximately -15%) in the prior-year period.
While growth in Germany continued to be very dynamic, this year's sales in the U.S. in the third quarter declined by about 15% from EUR 3.8 million in 2018. This is due to positive one-off effects in September 2018 before a price increase that took effect on October 1, 2018. The company continues to see the fourth quarter as the key revenue driver for its growing business in all markets.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611

Contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
E-mail: [email protected]


10-Oct-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: [email protected]
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 888181

 
End of Announcement DGAP News Service

888181  10-Oct-2019 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=888181&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 12,03 21,11 31,26 30,35 28,79 25,74 31,70
EBITDA1,2 -13,05 -17,72 -20,22 -4,70 27,95 1,87 4,20
EBITDA-Marge3 -108,48 -83,94 -64,68 -15,49 97,08 7,26
EBIT1,4 -13,93 -18,48 -23,38 -10,03 24,66 1,12 3,30
EBIT-Marge5 -115,79 -87,54 -74,79 -33,05 85,66 4,35 10,41
Jahresüberschuss1 -16,10 -9,58 -7,36 -13,02 33,86 -44,17 0,00
Netto-Marge6 -133,83 -45,38 -23,54 -42,90 117,61 -171,60 0,00
Cashflow1,7 -13,12 -13,43 -32,89 -2,85 30,44 -3,90 0,00
Ergebnis je Aktie8 -0,43 -0,20 -0,16 -0,24 0,68 -0,77 -0,08
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Baker Tilly

INVESTOR-INFORMATIONEN
©boersengefluester.de
Biofrontera
WKN Kurs in € Einschätzung Börsenwert in Mio. €
604611 0,347 22,14
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 2,18 0,00 -1,42
KBV KCV KUV EV/EBITDA
1,09 - 0,86 11,83
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 20.06.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
31.05.2023 31.08.2023 - 27.04.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-13,90% -36,79% -13,47% -70,34%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Biofrontera AG  ISIN: DE0006046113 können Sie bei EQS abrufen


Biotechnologie , 604611 , B8F , XETR:B8F